Loading
Codexis, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 04 Aug 2025.
Codexis, Inc.: what insiders have been doing
Codexis, Inc., founded in 2002, is a Healthcare & Pharma company based in Redwood City, United States. Its directors and officers file their transactions with SEC (Form 4). Over the twelve months to 18 October 2026, 15 filings were filed, from 9 insiders.
There is no open-market purchase to report; the filings show 11 sales worth €2.2M by 6 insiders. The totals do not cover 1 filing with an undisclosed amount. At €1.5M, the sale published on 14 November 2025 by Opaleye Management Inc. is the largest of the period.
Across the 5,812 companies tracked on its exchange, the median is 19 filings; at 15 filings, this issuer sits below that mark. Over the whole record (from 2016), the tally stands at 28 purchases and 28 sales. For the fiscal year to 31 December 2025, the annual 10-K puts revenue at 70.4 m USD and net income at -44.0 m USD.
Between a trade and the moment it shows up on SEC (Form 4), the median delay is 3 days. For comparison, the SEC allows two business days to file a Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
Other companies in the same sector with recent insider buying flagged by our signals: MAIA Biotechnology, Inc. and Cooper Companies, Inc. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
137
Thresholds
n/a
Buy Volume
€11M
28 ops. · all time
Sell Volume
€5M
28 ops. · all time
Who traded when
BuySaleOpaleye Management Inc.20 buys5 sales
Alison Moore3 sales
Georgia Erbez3 sales
Stefan Lutz3 sales
Raymond De Vre2 sales
Dennis P. Wolf1 sale
Since the insiders bought
- -50.5%Entry US$2.93 · Close at T+365 US$1.45
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 21,917 of 24,148 companies
21.4
score / 100
Value9
Quality34
FCF yld-18%
Earn yld-32%
EV/EBITDA·
ROE-69%
Gross mgn87%
Net mgn-62%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$1.32
Analyst consensus
7 analysts1.83/5
US$2.00Target US$6.14(+365%)US$11.00
Income statement
RevenueUS$70.4M
Gross profitUS$61M87% margin
EBITDA-US$33.9M-48% margin
Net income-US$44M-39.6% margin
Valuation
PER (forward)-4.1x
P/Book3.7x
Beta2.55
Balance sheet & cash
Market capUS$144.5M
Total debtUS$73.2M
Free Cash Flow-US$23.8M
Debt / Equity220%
Profitability & ownership
ROE-69.4%
ROA-11.7%
% insiders7.1%
% institutions70.2%
Last declaration on 14 October 2026
Declarations137 total
6,335 shares@ US$1.3606Common StockSEC:0001610717-26-000438:0
6,335 shares@ US$1.3606Common StockSEC:0001610717-26-000436:0
6,335 shares@ US$1.36060.0054% mcap30.2% of flowCommon StockSEC144:0001557930-26-000001
6,335 shares@ US$1.36060.0054% mcap30.2% of flowCommon StockSEC144:0001754937-26-000001
2,605 sharesCommon StockSEC:0001610717-26-000215:0
5,862 shares@ US$1.132937.1% of flowCommon StockSEC:0001610717-26-000073:0
2,492 shares@ US$1.307118.2% of flowCommon StockSEC:0001610717-26-000047:0
3,826 shares@ US$1.307123.9% of flowCommon StockSEC:0001610717-26-000046:0
3,826 shares@ US$1.307123.9% of flowCommon StockSEC:0001610717-26-000045:0
4,685 shares@ US$1.696844.8% of flowCommon StockSEC:0001610717-26-000007:0
148,318 shares@ US$1.74132.9% of flowCommon Stock, par value $0.001 per shareSEC:0001493152-25-025624:0
8,952 shares@ US$1.56264.1% of flowCommon StockSEC:0001610717-25-000386:0
85,000 shares0Common StockSEC:0001610717-25-000382:0
890,000 shares@ US$1.937219.5% of flowCommon Stock, par value $0.001 per shareSEC:0001493152-25-023486:0
1,413 shares@ US$1.74100.0% of flowCommon StockSEC:0001610717-25-000376:0
50,000 shares@ US$1.8473100.0% of flowCommon StockSEC:0001610717-25-000374:0
296,682 shares@ US$1.69685.7% of flowCommon Stock, par value $0.001 per shareSEC:0001493152-25-021897:0
6,239 shares@ US$2.505176.1% of flowCommon StockSEC:0001610717-25-000363:0
6,239 shares@ US$2.50576.1% of flowCommon StockSEC:0001610717-25-000362:0
84,220 shares@ US$2.682.6% of flowCommon Stock, par value $0.001 per shareSEC:0001641172-25-022060:0
Canonical exit: 29 Oct 2025 (T+90)
8,422 shares@ US$2.820.3% of flowCommon Stock, par value $0.001 per shareSEC:0001641172-25-021727:0
Canonical exit: 27 Oct 2025 (T+90)
100,000 shares@ US$2.824.7% of flowCommon Stock, par value $0.001 per shareSEC:0001641172-25-020566:0
Canonical exit: 16 Oct 2025 (T+90)
100,000 shares@ US$2.392.7% of flowCommon Stock, par value $0.001 per shareSEC:0001641172-25-017361:0
Canonical exit: 25 Sept 2025 (T+90)
100,000 shares@ US$2.252.5% of flowCommon Stock, par value $0.001 per shareSEC:0001641172-25-015281:0
Canonical exit: 10 Sept 2025 (T+90)
40,983 shares0Common StockSEC:0000905148-25-002135:0
25 of 137 declarations
About Codexis, Inc.
Codexis, Inc. (NASDAQ: CDXS) is a U.S.-based biotechnology and enzyme-engineering company headquartered in Redwood City, California, United States. The company is listed on the NASDAQ market, placing it within the U.S. public equity universe of specialized life-science small caps. Codexis was founded in 2002 and initially built itself as a platform company focused on enzyme optimization; over time, it has shifted toward higher-value pharmaceutical manufacturing applications while retaining the scientific core of its directed-evolution engine. ([codexis.com](https://www.codexis.com/about-us/history/?utm_source=openai))
At the center of Codexis’ business is its proprietary CodeEvolver® technology platform, used to discover, develop, and improve novel high-performance enzymes. Historically, the company has served pharmaceutical customers in small-molecule API and intermediate manufacturing, where engineered enzymes can help improve efficiency, selectivity, and sustainability versus more conventional chemistry routes. More recently, Codexis has sharpened its strategic focus around RNA therapeutics manufacturing, especially siRNA, through its ECO Synthesis® Manufacturing Platform. That platform is designed to support efficient, scalable enzymatic synthesis of complex RNA-based therapeutics, with particular emphasis on product quality, stereochemical control, and manufacturability. ([codexis.com](https://www.codexis.com/investors/sec-filings/annual-reports/content/0001200375-25-000003/0001200375-25-000003.pdf))
Read moreShow less
Competitive positioning is built on a combination of deep enzyme-engineering expertise, an established pharma customer base, and a differentiated value proposition around greener and potentially less capital-intensive manufacturing. Codexis addresses two overlapping markets: small-molecule pharmaceutical biocatalysis and RNAi manufacturing services/platform solutions. Management argues that many of its existing pharma relationships create a commercial bridge into RNA applications, since the same customer set is increasingly active in both small molecules and RNA therapeutics. The company’s principal competitors vary by segment, ranging from conventional chemical catalyst providers and contract manufacturers in biocatalysis to alternative RNA manufacturing approaches in the oligonucleotide space. ([codexis.com](https://www.codexis.com/investors/sec-filings/annual-reports/content/0001200375-25-000003/0001200375-25-000003.pdf))
Recent developments suggest a company in transition from research-led enzyme specialist to a more commercial therapeutics manufacturing platform. In 2025 and 2026, Codexis announced a $37.8 million technology transfer agreement with Merck, an evaluation agreement with Nitto Denko Avecia, and a contract to manufacture 50 grams of siRNA for a pharmaceutical innovator. The company also highlighted technical milestones, including larger siRNA batches and new data to be presented at TIDES USA, while pursuing an ECO GMP Manufacturing Center intended to support future scale-up, with full production capability planned by the end of 2027. For investors, Codexis remains a high-risk, technology-driven growth story whose valuation and trajectory will depend on execution, partnership conversion, and commercial adoption of ECO Synthesis. ([ir.codexis.com](https://ir.codexis.com/news-events/press-releases/detail/443/codexis-reports-fourth-quarter-and-fiscal-year-2025-financial-results))
